Abstract
Erlotinib is a reversible epidermal growth factor receptor tyrosine kinase inhibitor used to treat advanced non-small cell lung carcinoma patients who have shown progression on at least 1 prior chemotherapy regimen. Most of the patients on erlotinib show cutaneous adverse effects. We report the 18F-FDG PET/CT findings in a case of metastatic non-small cell lung carcinoma on erlotinib chemotherapy with developed skin toxicity.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Erlotinib Hydrochloride
-
Fluorodeoxyglucose F18
-
Humans
-
Lung Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Multimodal Imaging
-
Positron-Emission Tomography
-
Quinazolines / adverse effects*
-
Radiopharmaceuticals
-
Skin Diseases / diagnostic imaging*
-
Skin Diseases / etiology
-
Tomography, X-Ray Computed
Substances
-
Antineoplastic Agents
-
Quinazolines
-
Radiopharmaceuticals
-
Fluorodeoxyglucose F18
-
Erlotinib Hydrochloride